Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)
M. Reljanovic et al., Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II), FREE RAD RE, 31(3), 1999, pp. 171-179
Short-term trials with the antioxidant thioctic acid (TA) appear to improve
neuropathic symptoms in diabetic patients, but the long-term response rema
ins to be established. Therefore, Type 1 and Type 2 diabetic patients with
symptomatic polyneuropathy were randomly assigned to three treatment regime
ns: (1) 2 x 600 mg of TA (TA 1200), (2) 600 mg of TA plus placebo (PLA) (TA
600) or (3) placebo and placebo (PLA). A trometamol salt solution of TA of
1200 or 600 mg or PLA was intravenously administered once daily for five c
onsecutive days before enrolling the patients in the oral treatment phase.
The study was prospective, PLA-controlled, randomized, double-blind and con
ducted for two years. Severity of diabetic neuropathy was assessed by the N
europathy Disability Score (NDS) and electrophysiological attributes of the
sural (sensory nerve conduction velocity (SNCV), sensory nerve action pote
ntial (SNAP)) and the tibial (motor nerve conduction velocity (MNCV), motor
nerve distal latency (MNDL)) nerve. Statistical analysis was performed aft
er independent reviewers excluded all patients with highly variable data al
lowing a final analysis of 65 patients (TA 1200: n = 18, TA 600: n = 27; PL
A: n = 20). At baseline no significant differences were noted between the g
roups regarding the demographic variables and peripheral nerve function par
ameters for these 65 patients. Statistically significant changes after 24 m
onths between TA and PLA were observed (mean +/- SD) for sural SNCV: +3.8 /- 4.2 m/s in TA 1200, +3.0 +/- 3.0 m/s in TA 600, -0.1 +/- 4.8 m/s in PLA
(p < 0.05 for TA 1200 and TA 600 vs. PLA); sural SNAP: +0.6 +/- 2.5 mu V in
TA 1200, +0.3 +/- 1.4 mu V in TA 600, -0.7 +/- 1.5 mu Vin PLA (p = 0.076 f
or TA 1200 vs. PLA and p < 0.05 for TA 600 vs. PLA), and in tibial MNCV: +1
.2 +/- 3.8 m/s in TA 1200, -0.3 +/- 5.2 m/s in TA 600, -1.5 +/- 2.9 m/s in
PLA (p < 0.05 for TA 1200 vs. PLA). No significant differences between the
groups after 24 months were noted regarding the tibial MNDL and the NDS. We
conclude that in a subgroup of patients after exclusion of patients with e
xcessive test variability throughout the trial, TA appeared to have a benef
icial effect on several attributes of nerve conduction.